Investor Overview

Corporate Profile
ContraFect Corporation is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation).
Stock Quote
ExchangeNASDAQ CM (US Dollar)
Price$1.33
Change (%) Stock is Up 0.03 (2.31%)
Volume111,886
Data as of 07/25/17 12:06 p.m. ET
Minimum 20 minute delay
Refresh quote
Press ReleasesMore >>
DateTitle  
07/20/17ContraFect Corporation Prices $40 Million Public Offering of Common Stock and Warrants
YONKERS, NY -- (Marketwired) -- 07/20/17 -- ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the pricing of its underwritten public offering of 32,000,000 shares of its common stock and related warrants to purchase 16,000,000 shares of common stock with an exercise price of $1.55 per share at a combined public offering price of $1.2... 
 Printer Friendly Version
07/19/17ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants
YONKERS, NY -- (Marketwired) -- 07/19/17 -- ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that it has commenced an underwritten public offering of its common stock and warrants to purchase additional shares of its common stock. All of the securities in the offering are to be sold by ContraFect. Piper Jaffray & Co. is acting... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever ContraFect Corporation posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.
Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS |

Share

X
| E-mail Alerts E-mail Alerts | IR Contacts Contact IR | Financial Tear Sheet Tear Sheet